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In this work, we developed and validated an effective reversed-phase HPLC method with photodiode array 
(PDA) detection for the quantitative analysis of amphotericin B (AmB) in poly(lactide)-poly(ethylene 
glycol) (PLA-PEG) blend nanoparticles. Chromatographic runs were performed on a reverse phase 
C18 column using a mobile phase comprising a 9% acetic acid and acetonitrile mixture (40:60, v/v) 
under isocratic elution with a flow rate of 1 mL/min. AmB was detected at a wavelength of 408 nm. The 
validation process was performed considering the selectivity, linearity, precision, accuracy, robustness, 
limit of detection (LOD) and limit of quantitation (LOQ) of the method. A concentration range of  
1-20 µg/mL was used to construct a linear calibration curve. The LOQ and LOD were 55 and 18 ng/mL, 
respectively. The mean recovery of AmB from the samples was 99.92% (relative standard deviation (RSD) 
= 0.34%, n=9), and the method was robust for changes in the flow rate of the mobile phase (maximum 
RSD=4.82%). The intra- and inter-assay coefficients of variation were less than 0.59%. The method 
was successfully used to determine the entrapment efficiency of AmB in PLA-PEG blend nanoparticles.
Uniterms: Amphotericin B/determination. Amphotericin B/encapsulation. High performance liquid 
chromatography/reverse phase/quantitative analysis. Nanoparticles.
Neste trabalho desenvolveu-se e validou-se um efetivo método por cromatografia líquida de alta eficiência 
(CLAE) em fase reversa com detecção por fotodiodos para a análise quantitativa de anfotericina B 
(AmB) em nanopartículas compostas por blendas de poli(ácido lático)-polietilenoglicol (PLA-PEG). 
Corridas cromatográficas foram realizadas sob coluna C18 de fase reversa com fase móvel consistindo 
de ácido acético 9% e acetonitrila (40:60, v/v), em eluição isocrática com fluxo de 1 mL/min. A AmB 
foi detectada no comprimento de onda de 408 nm. O processo de validação foi realizado considerando a 
seletividade, linearidade, precisão, exatidão, robustez, limite de detecção (LD) e limite de quantificação 
(LQ) do método. Uma faixa de concentração entre 1-20 µg/mL foi usada para obter a curva-padrão linear. 
Os valores de LD e LQ foram 55 e 18 ng/mL, respectivamente. A recuperação média da AmB a partir 
das amostras foi de 99,92% (desvio padrão relativo = 0,34%, n=9) e o método foi robusto, considerando 
alterações no fluxo da fase móvel (desvio padrão relativo máximo=4,82%). Os coeficientes de variação 
intra e inter dia foram inferiores a 0,59%. O método foi utilizado com sucesso para a determinação da 
eficiência de encapsulação da AmB em nanopartículas de PLA-PEG.
Unitermos: Anfotericina B/determinação. Anfotericina B/encapsulação em nanopartículas. Cromatografia 
líquida de alta eficiência/fase reversa. Nanopartículas.
INTRODUCTION
Amphotericin B (AmB) is the most widely used 
antifungal agent for the treatment of systemic fungal 
infections and is also applied in visceral leishmaniasis 
(Kullberg, Pauw, 1999; Sundar, Chakravarty, 2013). It is a 
polyene macrolide antibiotic produced by an actinomycete, 
Streptomyces nodosus, first isolated in 1955, and was the 
first antifungal to be approved by the U.S. Food and Drug 
Administration (FDA), in 1965 (Wu, 1994). The AmB 
chemical structure has an amphipathic nature, which 
compromises its water solubility. Thus, in the presence of 
water, AmB has a tendency to self-aggregate and produce 
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dimers and oligomers, which is responsible for its affinity 
to ergosterol, a component of fungi cell membranes, and 
also cholesterol, a component of human cell membranes, 
which leads to its toxicity. The aggregated state of the 
drug is the cause of its serious side effects, such as 
nephrotoxicity, hepatotoxicity, hematotoxicity, and other 
complications related to AmB treatment (Espada et al., 
2008a; Espada et al., 2008b; Legrand et al., 1992; Adams, 
Kwon, 2003).
Many AmB formulations have been tested with 
the aim of maintaining the drug in the monomeric state 
and decreasing its toxicity. Some of them based on 
nanotechnology are already commercially available, such 
as the liposomal product Ambisome®, the lipid complex 
Abelcet® and the colloidal dispersion Amphocil®. These 
formulations, particularly the liposomal, increase the 
therapeutic index of the drug by reducing its toxicity but 
have the disadvantage of requiring parenteral infusion 
administration, requiring patient hospitalization, 
decreasing patient compliance and causing variability 
in pharmacokinetics (Vyas, Gupta, 2006; Adler-Moore, 
Proffitt, 2008; Barratt, Bretagne, 2007; Nahar et al., 2008). 
An alternative delivery system for AmB could circumvent 
these drawbacks by providing a safe and effective alternate 
route of administration, such as oral.
Polymeric nanoparticles may be important tools 
for addressing AmB solubility and pharmacokinetic 
drawbacks in order to reduce its toxicity. Polymeric 
nanoparticles present valuable physicochemical properties 
that improve the biological effects of the carried drug. 
By tailoring the particle size, surface charge, polymer 
composition and molecular weight, nanoparticles can 
be manipulated for a particular purpose. Nanoparticles 
optimize therapeutic regimens, decreasing the dose 
needed for treatment by prolonging drug release, which 
contributes to reducing drug toxicity (Kumari, Yadav, 
Yadav, 2010; Pinto Reis et al., 2006). Poly(ethylene 
glycol) (PEG) has been used to coat nanoparticles and 
prevent premature opsonization and phagocytosis, 
extending the half-life of nanoparticles and prolonging 
the drug release and its effects (Essa, Rabanel, Hildgen, 
2010; Nguyen et al., 2003).
A suitable drug delivery system must present 
high drug encapsulation efficiencies in order to reach 
its therapeutic goal. With the purpose of defining the 
drug content of nanoparticles, a quantitation method 
must be appropriately validated. Various methods have 
been described in the literature for determining the 
AmB content in samples, such as the use of biological 
matrices, high performance liquid chromatography 
(HPLC) (Italia, Singh, Kumar, 2009; Espada et al., 
2008; Eldem, Arican-Cellat, 2001), second-derivative 
spectrophotometry (Ganière Monteil et al., 1998), and 
liquid chromatography tandem mass spectrometry (LC–
MS/MS) (Deshpande et al., 2010). In lipid formulations, 
HPLC (Manosroi, Kongkaneramit, Manosroi, 2004a; 
Manosroi, Kongkaneramit, Manosroi, 2004b; Eldem, 
Arican-Cellat, 2000) and UV/Vis-spectrophotometry 
(Legrand et al., 1997; Larabi et al., 2004; Jung et al., 
2009) have been reported. For polymeric nanoparticles, 
most studies have achieved the analytical determination 
of AmB by UV-Vis spectrophotometry (Vyas, Gupta, 
2006; Van de Ven et al., 2012; Xu et al., 2011, Shim 
et al., 2011; Falamarzian, Lavasanifar, 2010). In the 
context of HPLC methods to quantify AmB in polymeric 
nanoparticles, the study of Nahar et al. (2008) cites an 
HPLC method, but details such as the peak characteristics 
and validation data were not described. Therefore, the 
aim of this work was to develop and validate a simple and 
rapid reverse phase HPLC method with PDA detection 
to determine the encapsulation efficiency of AmB in 
poly(lactide)-poly(ethylene glycol) (PLA-PEG) blend 
nanoparticles.
MATERIAL AND METHODS
Material
Amphotericin B (AmB), poly(lactide) (PLA) (MW 
85-160 kDa), poly(ethylene glycol) (PEG) (MW 10 kDa) 
and polyvinyl alcohol (PVA, 31 KDa, 88% hydrolyzed) 
were purchased from Sigma-Aldrich (USA). Chloroform 
and dimethyl sulfoxide (DMSO) were purchased from 
Biotec® (Brazil), and dichloromethane was obtained 
from FMaia® (Brazil). HPLC-grade solvents, such as 
methanol, acetonitrile and acetic acid, were purchased 
from JTBaker® (USA). Water was purified using a Milli-Q 
Plus system (Millipore®).
Instrumentation
A Waters 2695 Alliance HPLC system (Milford, 
MA, USA) was used for method development. The HPLC 
system was equipped with a column compartment with 
temperature control, an on-line degasser, a quaternary 
pump, an auto sampler and a photodiode array (PDA) 
wavelength detector (Waters 2998). Data acquisition, 
analysis, and reporting were performed using Empower 
chromatography software (Milford, MA, USA). HPLC 
analysis was conducted using a RP C18 column (Xterra 
Waters®) with a 5 µm particle size, a 4.6 mm internal 
diameter and a 250 mm length.
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Chromatographic conditions
The mobile phase comprised a 9% acetic acid and 
acetonitrile mixture (40:60, v/v) under isocratic elution 
with a flow rate of 1 mL/min. The sample injection volume 
was 20 µL, and the PDA detector was set at a wavelength 
of 408 nm. The analysis was performed at a temperature 
of 25 °C and the method run time was 6 min.
Preparation of standards and samples
A stock standard solution of 1 mg/mL of AmB was 
prepared in DMSO, and subsequent dilutions in methanol 
were performed to obtain seven standard solutions (1, 2, 3, 
4, 5, 10 and 20 µg/mL). Similarly, seven standard solutions 
in methanol were obtained (0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 
2.0 µg/mL) to determine the limit of detection (LOD) and 
limit of quantitation (LOQ) of this method. The samples 
were appropriately diluted in methanol. The standards and 
samples had previously been filtered through a 0.22 μm 
pore size filter (Millipore, Bedford, USA) prior to injection.
System suitability of the developed method
The system suitability parameters were studied to 
verify the system performance. Six replicate standards 
containing AmB (10 μg/mL) were analyzed using the 
developed method. Factors such as the theoretical plate 
count, the tailing factor and the capacity factor were taken 
into consideration for testing the system suitability.
Method validation
The HPLC method was validated according to 
the International Conference on Harmonization (ICH) 
guidelines (2005). The following characteristics were 
considered for validation: specificity, linearity, robustness, 
precision, accuracy, range, LOD and LOQ. The specificity 
was evaluated by comparing representative chromatograms 
from samples containing possible interfering substances 
and samples containing AmB. Additionally, the specificity 
was demonstrated by performing stress studies (i.e., pH 
and temperature variation, oxidation and light stability).
The linearity was determined by calculating a 
regression line from the plot of peak area vs. concentration 
for the seven standard solutions in methanol (i.e., 1, 2, 
3, 4, 5, 10 and 20 µg/mL) using the linear least squares 
methodology.
Analysis of three different AmB standards (1, 10 and 
20 µg/mL) three times each on the same day was carried 
out to evaluate the repeatability or intra-day precision. 
The intermediate precision was determined by analyzing 
the three standard solutions on three different days. The 
precision results were reported as the standard deviation 
(SD) and the relative standard deviation (RSD).
The accuracy was determined by calculating the 
percent recovery of the mean concentration of AmB at 
three different concentrations (1, 10 and 20 µg/mL), and 
the RSD was determined. The mean concentration value 
obtained for each level was compared to the theoretical 
value, which was considered to be 100%.
The robustness was evaluated by deliberately varying 
the flow rate (0.9 and 1.1 mL/min) of the mobile phase.
The LOD and LOQ were determined from the 
specific calibration curve obtained using seven standard 
solutions (0.2, 0.4, 0.6, 0.8, 1.0, 1.5 and 2.0 µg/mL) that 
were closest to the LOQ. The following equations (1 and 
2) were used according to ICH (2005):
 LOD = 3.3σ/S Eq. 1
 LOQ = 10σ/S Eq. 2
where σ is the standard deviation of the response, and 
S is the slope of the calibration curve. All samples were 
analyzed in triplicate.
Method applicability
Preparation of AmB-loaded PLA-PEG blend 
nanoparticles
PLA-PEG blend nanoparticles containing AmB 
were prepared using an oil-in-water (O/W) emulsification/
solvent evaporation technique. First, PLA and PEG at a 
PLA:PEG ratio of 5:1 were dissolved in dichloromethane. 
They were then added to an organic solution (DMSO 
and chloroform) containing AmB, which was emulsified 
into a PVA aqueous solution (1%, m/v) and sonicated for 
5 min to produce an O/W emulsion. The emulsion was 
subjected to evaporation under vacuum with continuous 
stirring at 37°C. The nanoparticles were isolated from the 
non-encapsulated drug by ultracentrifugation (19,975 × g, 
30 min, 4 °C) and washed twice with ultrapure water. The 
precipitate was suspended in 5% sucrose and freeze-dried. 
The resultant supernatants were collected for further 
analyses. Additional details regarding the methods used 
in this study are in the deposited patent in the Instituto 
Nacional de Propriedade Industrial (INPI) in Brazil 
(PI#1107205-9 A2) (Mainardes et al., 2011) and are 
protected according to the Brazilian regulatory agency.
The mean nanoparticle size and size distribution 
were analyzed using dynamic light scattering (BIC 90 plus, 
Brookhaven Instruments Corp.). The measurements were 
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performed at a scattering angle of 90° at 25 °C. For each 
sample, the mean particle diameter, polydispersity and 
standard deviation for ten determinations were calculated.
Determination of AmB encapsulation efficiency
To determine the encapsulation efficiency (EE), 
an indirect analysis was performed. The supernatant-
containing free AmB obtained from the ultracentrifugation 
of nanoparticles was appropriately diluted in methanol, 
and the samples were analyzed by the HPLC method 
described in this work. The measurements were 
performed in triplicate. The amount of AmB loaded in the 
nanoparticles was calculated by subtracting the quantity 
in the supernatant from the total used initially using the 
following equation (eq. 3):
% EE = theoretical amount – analytical amount/
theoretical amount x 100  Eq. 3
RESULTS AND DISCUSSION
Method development
Initially, the analyses were performed using 
acetonitrile and water in variable proportions to the 
mobile phase. Although the retention time was less than 
4 min, the peaks presented no symmetry. Alternatively, a 
mobile phase consisting of acetonitrile and sodium acetate 
buffer was tested, but there were no peaks after a run of 
40 min. When methanol and water were tested as eluents 
in a proportion of 75:25 (v/v), a peak was observed after 
11 min but presented an irregular shape. Methanol and 
sodium acetate buffer (25:75, v/v) were tested, and despite 
presenting a short retention time of approximately 3 min, a 
noticeable tailing of the AmB peak was observed. Lastly, a 
mobile phase consisting of acetonitrile and 9% acetic acid 
was used. After some modifications to the proportions of 
the eluents, a regular and symmetric peak was detected at 
approximately 4.5 min (Figure 1) using acetonitrile and 
9% acetic acid (60:40, v/v) with a flow rate of 1 mL/min.
System Suitability 
The system suitability of this method was evaluated 
by analyzing the capacity factor, the peak symmetry 
and the theoretical plates of the column during the run 
of the AmB methanol solution over six repetitions. The 
developed method produced a theoretical plate number 
of over 2000, with a tailing factor less than 1.5 and a 
capacity factor less than 2, which ensures the suitability 
of the developed method. The system suitability results 
are summarized in Table I; it can be observed that the 
TABLE I – System suitability of the HPLC method
Chromatographic 
Parameter Result*
Acceptance 
Criteria
Capacity factor (K’) 1.25 ± 0.2 K’ < 2
Tailing factor (T) 1.084 ± 0.057 T < 2
Theoretical plates (N) 2600.72 ± 46.87 N > 2000
* Presented as mean value ± standard deviation (n = 3)
FIGURE 1 - Representative HPLC chromatogram of a 20 µg/mL AmB standard solution. Conditions: mobile phase, 9% acetic 
acid:acetonitrile (40:60, v/v); flow rate, 1 mL/min; PDA detector, 408 nm; column temperature, 25 °C; injection volume, 20 µL.
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FIGURE 2 - Representative HPLC chromatograms of the AmB sample (AmB in supernatant from the nanoparticles) (A) and of 
the supernatant from the blank nanoparticles (B). Conditions: mobile phase, 9% acetic acid:acetonitrile (40:60, v/v); flow rate, 
1 mL/min; PDA detector, 408 nm; column temperature, 25 °C; injection volume, 20 µL.
parameters analyzed were in accordance with acceptance 
criteria (Sutariya, Wehrung, Geldenhuys, 2012; Hussen, 
Shenoy, Krishna, 2013).
Method validation
Specificity
The specificity of the method was evaluated by 
comparing the chromatograms of both the AmB standards 
and the samples to those of potential interfering formulation 
components. For this study, blank nanoparticles (without 
AmB) were prepared as described previously, and the 
supernatant obtained after their ultracentrifugation was 
diluted with methanol and analyzed by the described 
HPLC method. The representative chromatogram of 
the AmB sample (Figure 2A) showed an AmB peak at 
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approximately 4.5 min, which was in agreement with 
that obtained for the AmB standard (Figure 1). No peaks 
at this retention time were observed in the chromatogram 
of the supernatant from the blank nanoparticles (Figure 
2B), which indicates there was no interference in the 
quantitative determination of AmB from the formulation 
components.
Additionally, the specificity of the method was 
assessed by submitting AmB to stress conditions (i.e., 
temperature, visible light, pH and oxidation) to detect the 
occurrence of possible interfering peaks at 408 nm resulting 
from the degradation of AmB. These tests are regarded as 
helpful tools in establishing degradation pathways and 
the inherent stability of the molecule and help validate the 
ability of the method to study drug stability (Das Neves 
et al., 2010). The results are presented in Table II. The 
percent recovery under stress conditions revealed that AmB 
was affected by visible light, oxidation and pH variations, 
although there were no degradation peaks. The acid pH 
did not result in an AmB peak most likely because the acid 
conditions were very severe. Ideally, the study would be 
initiated with 0.1 M HCL (Silva et al., 2009). This method 
can be considered specific due to the absence of interfering 
peaks in the AmB retention times.
Linearity
The linearity was evaluated at seven concentrations 
ranging from 1 to 20 μg/mL by calculating the regression 
equation (Eq. 4) and the correlation coefficient (r) using 
the method of least squares:
 Y = 9.86.104 × A – 8.64.103  Eq. 4
 r = 0.9998
where Y is the peak area and A is the standard solution 
concentration in μg/mL. The r -value near 1 indicates 
linearity in the proposed range.
The validity of the assay was confirmed by an 
analysis of variance, which showed that the linear 
regression was significant and the deviation from linearity 
was not significant (p<0.01).
Precision
Precision is a measure of the relative error for the 
method and is expressed as the RSD of the repeatability 
and intermediate precision. Three concentrations of AmB 
(1, 10 and 20 µg/mL) were prepared in triplicate and 
analyzed over either one or three different days to evaluate 
the intra- and inter-day variations, respectively. The RSD 
of the responses were calculated for each case and are 
shown in Table III, presenting a maximal RSD of 0.59%, 
which indicates precision.
Accuracy
The accuracy was assessed by calculating the percent 
recovery and the RSD of the mean concentration of the 
analyte at three different concentrations (1, 10 and 20 µg/
mL). The detailed results are presented in Table IV. The 
mean percent recovery of AmB from the samples was 
99.92% (RSD = 0.34%, n=9), which indicates agreement 
between the experimental and theoretical values.
Robustness
A robustness assay is used to verify the influence 
of small changes in the analytical procedures/parameters 
on the response. The evaluation of robustness was based 
on the percent recovery and RSD values obtained using 
different parameters for the flow rate of the mobile phase. 
The method was robust concerning these alterations in 
chromatographic parameters (Table V). The maximum 
RSD obtained was 4.82%.
Limit of quantitation and limit of detection
The lowest concentration at which the analyte could 
TABLE II - Specificity to AmB under stress conditions 
Condition
Percentage of Recovery (%) ± RSDa (n=3)
1 µg/mL 10 µg/mL 20 µg/mL Mean
Reference (none) 
Visible light (24 h)
99.66 ± 0.57 
98.33 ± 1.52
100.03 ± 0.11 
94.47 ± 2.54
99.83 ± 0.29 
90.00 ± 3.90
99.84 ± 0.33 
94.27 ± 2.66
Freeze: -18o C (24 h) 100.66 ± 1.53 96.33 ± 2.31 97.16 ± 0.57 98.05 ± 1.47
Oxidation: H2O2 (2 h) 
pH variation (2 h) 
Basic: NaOH (1 M)
24.33 ± 7.76 
 
16.33 ± 0.57
14.00 ± 2.20 
 
23.00 ± 2.64
21.10 ± 5.14 
 
1.48 ± 0.10
19.81 ± 5.03 
 
13.60 ± 1.11
Acid: HCl (1 M) - - - -
aRSD = relative standard deviation
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low-end region of the proposed range. The method was 
linear in this range because the r-value was 0.998. The 
LOD and LOQ were found to be 18.0 and 55.0 ng/mL, 
respectively.
Range
The working range of the method, defined as the 
range that exhibited the required linearity, accuracy 
and precision, was between the LOQ and 20 µg/mL. 
Consequently, samples at these concentrations can be 
assayed using the proposed HPLC method.
Method applicability
The proposed analytical method was performed 
to evaluate the encapsulation efficiency of AmB in 
PLA-PEG blend nanoparticles. The indirect method was 
chosen, in which the supernatant containing free AmB was 
analyzed using HPLC. Through the specificity test, it was 
demonstrated that no interfering or unusual peaks were 
observed in the chromatograms during drug quantitation.
The nanoparticles containing AmB were successfully 
obtained by the emulsion-solvent evaporation method. 
The mean diameter of the nanoparticles was 223 ± 25 nm 
(n=3), but a bimodal size distribution profile was obtained, 
as can be observed in Figure 3. The encapsulation 
efficiency of AmB in the PLA-PEG blend nanoparticles 
was 68.9 ± 4.5% (n=3). This value is considered high 
considering the amphiphilic characteristic of AmB. The 
work of Verma, Pandya and Mishra (2011) describes a 
drug entrapment efficiency of 42.5 ± 6.41% for AmB 
in poly(lactide-co-glycolide) nanoparticles. Therefore, 
the PLA-PEG nanoparticles developed in this work are 
potential carriers for AmB, and its effectiveness and 
toxicity are under investigation.
One of the characterization steps for polymeric 
nanoparticles is the determination of their drug content. 
This parameter must be properly verified because the drug 
must be efficiently loaded into the nanoparticles to achieve 
the desired therapeutic efficacy. Therefore, a suitable and 
TABLE III - Precision results for the different levels of AmB in 
the standard solutions
Standard solution 
(µg/mL)*
Measured 
concentration ± SDa 
(µg/mL)
RSDb 
(%)
Analysis repeatability (n=3)
1 0.99 ± 0.006 0.58
10 10.00 ± 0.04 0.44
20 20.00 ± 0.04 0.21
Intermediate precision (n=3)
Day 1
1 0.99 ± 0.005 0.58
10 10.00 ± 0.01 0.12
20 19.96 ± 0.06 0.29
Day 2
1 0.99 ± 0.005 0.58
10 10.03 ± 0.015 0.12
20 20.02 ± 0.05 0.26
Day 3
1 0.98 ± 0.006 0.59
10 10.02 ± 0.015 0.15
20 20.03 ± 0.03 0.13
*n=3; aSD = Standard deviation; bRSD = relative standard 
deviation
TABLE IV - Accuracy results for the AmB concentrations in the 
standard solutions
Standard solution 
(µg/mL)*
Recovery (%) RSDa (%)
1 99.66 0.58
10 100.23 0.23
20 99.88 0.21
*n=3; aRSD = relative standard deviation
TABLE V - Robustness results for the different flow rates
Changes to original 
method*
Percentage of Recovery (%) ± RSDa (n=3)
1 µg/mL 10 µg/mL 20 µg/mL Mean
None 99.66 ± 0.57 100.27 ± 0.15 100.08± 0.26 100.00 ± 0.32
0.9 mL/min 100.00 ± 2.64 99.00 ± 2.00 100.83± 0.57 99.94 ± 1.06
1.1 mL/min 96.00 ± 2.65 94.00 ± 2.00 93.66 ± 4.82 94.55 ± 3.15
*1 mL/min. aRSD = relative standard deviation
be detected (LOD) or quantified (LOQ) with acceptable 
precision and accuracy was calculated from the SD of the 
response and the slope obtained from the linear regression 
of the specific calibration curve (0.2-2.0 µg/mL) in the 
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validated quantitation method is required to assess this 
parameter (Do Nascimento et al., 2012).
In this work, we developed a simple, fast and 
effective HPLC method to quantitatively analyze AmB 
in PLA-PEG blend nanoparticles. The literature describes 
mainly spectrophotometric methods for AmB quantitation 
in nanoformulations (Vyas, Gupta, 2006; Van de Ven et 
al., 2012; Xu et al., 2011, Shim et al., 2011; Falamarzian, 
Lavasanifar, 2010), but these methods are not as 
convenient as HPLC methods in terms of sensitivity. One 
of the few studies using HPLC-UV/Vis was proposed by 
Nahar et al., (2008) and used a mobile phase composed 
of acetonitrile:1% acetic acid:water (41:43:16, v/v/v) at a 
flow rate of 1.5 mL/min and achieved an AmB retention 
time of 4.3 min. Despite the high flow rate and increased 
solvent consumption, the method seems appropriate; 
however, the authors only cited the chromatographic 
conditions and did not provide any information about the 
peak characteristics or method validation.
The HPLC method developed and validated in this 
work represents an alternative to other methodologies 
and provides detailed data for the analysis of AmB 
in nanoparticles via HPLC-PDA detection. The short 
retention time of AmB allowed the analysis of a large 
number of samples in a short period of time with reduced 
solvent costs.
CONCLUSION
The HPLC method using PDA detection for 
determining the encapsulation efficiency of AmB in PLA-
PEG nanoparticles fulfilled all of the requirements to be 
considered a reliable and feasible method of analysis and 
could also be applied for other assays involving AmB-
loaded nanoparticles, such as in vitro AmB release profile 
and stability studies.
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